StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities researchers at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Dawson James started coverage on Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They set a “buy” rating and a $3.00 price objective on the stock.

Tonix Pharmaceuticals Trading Up 5.3 %

Shares of Tonix Pharmaceuticals stock opened at $0.17 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.81 and a current ratio of 2.53. The firm has a 50-day moving average of $0.27 and a 200-day moving average of $0.37. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $3.31. The stock has a market cap of $14.24 million, a PE ratio of -0.02 and a beta of 2.21.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The firm had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.95 million. As a group, sell-side analysts forecast that Tonix Pharmaceuticals will post -3.71 EPS for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals makes up about 0.5% of Sabby Management LLC’s holdings, making the stock its 6th biggest holding. Sabby Management LLC owned about 7.02% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.